Resumen de Investigación

Lixisenatide shows no significant effect on arterial stiffness in diabetes.

Moderate confidence
Low bias
Última actualización 8 de julio de 2026

Conclusión Clave:

The study evaluated the impact of lixisenatide on aortic pulse wave velocity in patients with CKD and type 2 diabetes, finding no significant changes.

Estudio de un Vistazo

Qué se estudió

24 weeks of treatment with lixisenatide compared to placebo in adults with type 2 diabetes and CKD.

Participantes

Young Adult (19–39), Middle Aged (40-64)

Male, Female

with T2 Diabetes

Intervención

Lixisenatide

Resultados

Aortic pulse wave velocity, Albuminuria, HbA1c

Financiamiento

No Patrocinado por la Industria

Guarda este estudio y agrega notas a tu biblioteca de investigación.

Efectos Principales

Ao-PWV did not change significantly from baseline after 24 weeks, p = 0.38.

No significant changes were observed in albuminuria, p = 0.09.

HbA1c decreased with lixisenatide compared to placebo.

Resumen de Evidencia

InterventionOutcomeMeasured ChangeStudy Effect
Medications
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)
(Medications)
Clinical Outcomes
Albuminuria
(Clinical Outcomes)
No Change
Unclear
Medications
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)
(Medications)
Clinical Outcomes
Change in aortic pulse wave velocity from baseline to week 24
(Clinical Outcomes)
No Change
Unclear
Medications
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)
(Medications)
Glycemic Control
HbA1c
(Glycemic Control)
Decrease
Unclear

Unlock Full Evidence Analysis

Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.

evidence suggest

La Evidencia Sugiere

  • Ao-PWV remained stable at 9.65 m/s with lixisenatide versus 9.96 m/s with placebo.
  • Albuminuria showed no significant change, p = 0.09.
  • HbA1c levels decreased with lixisenatide, indicating improved blood sugar control.
who this applies

A quién se aplica

  • Adults with chronic kidney disease (CKD).
  • Individuals diagnosed with type 2 diabetes.
keep in mind

Tener en Cuenta

  • Results may not apply to populations outside of those studied.
  • The study focused on short-term effects; long-term implications are unknown.
  • Further research is needed to explore other potential benefits of lixisenatide.
between the lines

Entre Líneas

  • The study may have limited generalizability due to specific population characteristics.
  • Sample size and duration may not have been sufficient to detect subtle changes.
  • The study did not assess long-term effects beyond 24 weeks.

Unlock Full Analysis

Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.

Already have an account?

Referencia de la Revista

Nikolaos F, Panagiotis P, Dimitra S, et al. In people with CKD and type 2 diabetes the use of short-acting GLP-1 RA lixisenatide did not significantly influence Ao-PWV. Diabetes, Obesity & Metabolism. 2026;28(4):2953-2961. doi:10.1111/dom.70481

View DOIView on PubMedView on PMC

Connected Evidence

Discover how this study fits into the broader diabetes evidence landscape.

This study contributes to evidence on Insulin Therapies and HbA1c.

Relaciones de evidencia relacionadas

Explore in Evidence Archive

This study contributes to the evidence on the following intervention–outcome relationships.

Preguntas que esta evidencia ayuda a responder

Key clinical and research questions this study contributes to.

Does insulin glargine/lixisenatide fixed-ratio combination (iglarlixi) improve HbA1c?

Based on connected evidence for Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) and HbA1c.

Cómo se generan las conexiones

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.